- |||||||||| CWP291 / JW Pharma
Journal: Wnt/β-Catenin Inhibition by CWP232291 as a Novel Therapeutic Strategy in Ovarian Cancer. (Pubmed Central) - Jun 4, 2022
Noticeably, CWP232291 could also s suppress the growth of cisplatin-resistant cell lines and ovarian cancer patient-derived organoids. Overall, this study has firstly demonstrated the anti-tumor effect of CWP232291 in ovarian cancer and proposed Wnt/β-catenin pathway inhibition as a novel therapeutic strategy against ovarian cancer.
- |||||||||| CWP291 / JW Pharma
Journal: Smad4 and p53 synergize in suppressing autochthonous intestinal cancer. (Pubmed Central) - May 15, 2022
Overall, this study has firstly demonstrated the anti-tumor effect of CWP232291 in ovarian cancer and proposed Wnt/β-catenin pathway inhibition as a novel therapeutic strategy against ovarian cancer. Smad4 loss and p53 loss are synergistic in autochthonous intestinal carcinogenesis, by downregulating p21 and activating Wnt/β-catenin pathway.
- |||||||||| CWP291 / JW Pharma
Trial completion date, Trial primary completion date, Combination therapy: Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients (clinicaltrials.gov) - Dec 13, 2021
P1b/2a, N=45, Active, not recruiting,
Smad4 loss and p53 loss are synergistic in autochthonous intestinal carcinogenesis, by downregulating p21 and activating Wnt/β-catenin pathway. Trial completion date: Oct 2020 --> Oct 2022 | Trial primary completion date: Oct 2020 --> Oct 2022
- |||||||||| Review, Journal: Recent updates on Wnt signaling modulators: a patent review (2014-2020). (Pubmed Central) - Nov 5, 2021
Antibody based Wnt modulator, OTSA101-DTPA-90Y is currently under Phase I for the treatment of relapsed or refractory synovial sarcoma while OMP-18R5 is under Phase I for metastatic breast cancer. Ongoing preclinical and clinical trials will define the role of the Wnt pathway in different therapeutic areas and have opened new opportunities.
- |||||||||| CWP291 / JW Pharma
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients (clinicaltrials.gov) - May 17, 2019
P1a/1b, N=25, Completed,
Beyond providing preclinical evidence of therapeutic efficacy for the novel small molecule β-catenin inhibitor CWP232291 in CRPC, our results show that inducing ER stress and targeting WNT/β-catenin signaling may be a novel strategy against CRPC. Recruiting --> Completed | N=60 --> 25 | Trial completion date: Sep 2019 --> Oct 2018 | Trial primary completion date: Sep 2019 --> Oct 2018
- |||||||||| CWP291 / JW Pharma
Enrollment closed, Combination therapy: Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients (clinicaltrials.gov) - May 17, 2019
P1b/2a, N=45, Active, not recruiting,
Recruiting --> Completed | N=60 --> 25 | Trial completion date: Sep 2019 --> Oct 2018 | Trial primary completion date: Sep 2019 --> Oct 2018 Recruiting --> Active, not recruiting
- |||||||||| CWP291 / JW Pharma
Phase classification, Trial primary completion date, Combination therapy: Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients (clinicaltrials.gov) - Mar 19, 2018
P1a/1b, N=60, Recruiting,
Recruiting --> Active, not recruiting Phase classification: P1 --> P1a/1b | Trial primary completion date: Jul 2017 --> Sep 2019
- |||||||||| CWP291 / JW Pharma
Enrollment open, Combination therapy: Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients (clinicaltrials.gov) - Mar 17, 2017
P1b, N=40, Recruiting,
Phase classification: P1 --> P1a/1b | Trial primary completion date: Jul 2017 --> Sep 2019 Not yet recruiting --> Recruiting
- |||||||||| CWP291 / JW Pharma
Enrollment open, Trial initiation date, Trial primary completion date, Combination therapy: Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients (clinicaltrials.gov) - Mar 8, 2016
P1, N=60, Enrolling by invitation,
Recruiting --> Completed Not yet recruiting --> Enrolling by invitation | Initiation date: Jun 2015 --> Oct 2015 | Trial primary completion date: Jul 2015 --> Jul 2017
- |||||||||| CWP291 / JW Pharma
Enrollment change, Trial primary completion date: Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients (clinicaltrials.gov) - Feb 10, 2015
P1, N=60, Recruiting,
Not yet recruiting --> Enrolling by invitation | Initiation date: Jun 2015 --> Oct 2015 | Trial primary completion date: Jul 2015 --> Jul 2017 N=48 --> 60 | Trial primary completion date: Dec 2014 --> Dec 2015
|
